TrialESMO open2026

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).

A Navarro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.